Developing the IL-36 receptor antagonist as a therapy for colon cancer
The immune system is rapidly emerging as a key player in the development and progression of cancer. Whilst the body’s immune system is designed to detect and destroy cancer cells, tumours are known to produce proteins that suppress the immune response. A better understanding of the relationship between tumours and the immune system will allow for the development of better therapies to fight cancer. In this proposal we will explore the role of one recently identified immune protein, IL-36, in colon cancer progression and spread, and examine whether this protein represents a new therapy in the fight against cancer.
- Award Date
- 01 July 2022
- Award Value
- €240,434.00
- Principal Investigator
- Dr Elizabeth Brint
- Host Institution
- University College Cork
- Scheme
- Investigator Led Projects